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Background. This study was conducted to investigate the clinical characteristics and treatment results of osteosarcoma in pediatric
patients during the past 30 years. Trends in survival rates and long-term toxicity were analyzed. Procedure. 130 pediatric patients
under the age of 20 years with primary localized or metastatic high-grade osteosarcoma were analyzed regarding demographic,
treatment-related variables, long-term toxicity, and survival data. Results. Comparison of the diﬀerent time periods of treatment
showed that the 5-year OS improved from 58.6% for children diagnosed during 1979–1983 to 78.6% for those diagnosed during
2003–2008 (P = 0.13). Interestingly, the basic treatment agents including cisplatin, doxorubicin, and methotrexate remained the
same. Treatment reduction due to acute toxicity was less frequent in patients treated in the last era (7.1% versus 24.1% in patients
treated in 1979–1983; P = 0.04). Furthermore, late cardiac eﬀects and secondary malignancies can become evident many years
after treatment. Conclusion. We elucidate the prevalence of toxicity to therapy of patients with osteosarcoma over the past 30 years.
The overall improvement in survival may in part be attributed to improved supportive care allowing regimens to be administered
to best advantage with higher tolerance of chemotherapy and therefore less chemotherapy-related toxicity.
1. Introduction
Osteosarcoma comprises 5% of all pediatric malignancies
and is the most common primary bone cancer in children
and adolescents. It is a highly aggressive tumor that usually
involves the metaphysis of long bones and metastasizes
primarily to the lung. Before the 1970s, the prognosis
for patients with high-grade osteosarcoma was poor, with
long-term survival rates of less than 20% [1]. Advances
in adjuvant and neoadjuvant chemotherapy have improved
the 5-year disease-free survival to more than 60% [2].
Since then diﬀerent attempts have been made to further
improve prognosis. However, it has been demonstrated that
neither dose intensification nor addition of newer agents
does improve survival [3–6]. Furthermore, patients that
survive experience prolonged periods of rehabilitation after
long periods of chemotherapeutic treatment and after often
disabling surgery. Although the long-term toxicities have
not been assessed completely, cardiotoxicity already emerged
as a significant price of cure for survivors of osteosarcoma
patients [7]. Monitoring trends in survival and the long term
toxicities is essential to enhance current treatment regimens.
To gain more insight in the young patients, as osteosar-
coma is predominantly being a disease that aﬀects young
patients, we investigate survival trends in this patient group
and subsequently analyze the occurrence of long term
toxicity over the last three decades.
2. Material and Methods
2.1. Patients. In total 130 pediatric patients were consec-
utively treated between 1979 and 2008 in two diﬀerent
centers: Radboud University Nijmegen Medical Centre and
University Medical Centre Groningen. All patients under
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the age of 20 years with newly diagnosed, primary local-
ized, or metastatic high-grade osteosarcoma were evaluated.
Complete clinical and pathologic records and appropriate
data regarding followup were present. Informed consent was
obtained for all patients.
2.2. Treatment. Information from the patients’ medical
charts about cumulative dosage of treatment, treatment
response (good responders defined as <10% vital cells
after neoadjuvant therapy), reduction of chemotherapy
(defined as >15% reduction of planned chemotherapy),
and surgical approach was collected. The overall period
was split into subperiods relating to the major changes in
protocol (1979–1983, 1984–2002, and 2003–2008). In the
first era from 1979–1983 a T10-based multidrug regimen
consisting of six cycles of doxorubicin 30mg/m2 daily for
2-3 consecutive days, six cycles of cisplatin 120mg/m2
administered by repeated 6 hours infusions, 8–12 cycles
of high-dose methotrexate 8–12mg/m2 with appropriate
folinic acid rescue, and 1-2 cycles of BCD was used. From
1984 to 2002 trials with control arm treatment of six cycles of
doxorubicin 25mg/m2 daily for 3 days in combination with
cisplatin 100mg/m2 as a continuous infusion were used. The
comparison arm consisted of only four doxorubicin/cisplatin
courses and additionally 12 courses of high-dose methotrex-
ate 12mg/m2 with appropriate folinic acid rescue. In the
last era from 2003 to 2008 patients was treated with six
cycles of doxorubicine 25mg/m2 daily for 3 days, four cycles
of cisplatin 120mg/m2 as a continuous infusion, and 12
cycles of high-dose methotrexate 8–12 g/m2 with appropriate
folinic acid rescue.
2.3. Survival. Overall survival (OS) and disease-free survival
(DFS) were estimated using the Kaplan-Meier method [8].
OS was defined as the interval between diagnosis and death
from any cause. Patients alive at the date of last followup were
censored at that time point. DFS was defined as the inter-
val between diagnosis and disease progression/recurrence.
Patients without disease recurrence at the date of last
followup were censored at that date. Cox’s proportional
hazard regression analysis was used to determine signifi-
cance of diﬀerences in survival curves. Confidence intervals
were calculated at the 95% level. We evaluated gender,
location, stage, treatment, treatment response, and toxicity-
induced reduction of chemotherapy as prognostic factors.
Associations between outcome and potential predictors were
evaluated with the Fisher’s exact test for categorical variables.
Statistical analysis was performed using SSPS software
(version 16.0, SSPS Inc, Chicago, IL, USA).
2.4. Long-Term Toxicities. Long-term toxicities after chemo-
therapeutic treatment were evaluated regarding development
of secondary malignancies, cardiotoxicity, and ototoxicity.
The length of time at risk for the secondary malignancy
neoplasm (SMN) was calculated from the date of diagnosis
of primary osteosarcoma until the date of diagnosis of
the second malignancy. The cumulative incidence rate of
second malignancies was calculated based on the method
of Gray [9]. For the analysis of cardiac toxicity resulting
from doxorubicin therapy, we included surviving patients
who underwent serial echocardiographic evaluations before,
during, and at least one followup echocardiogram after the
initial treatment with doxorubicin. An echocardiogram at
the end of chemotherapy was recommended annually for 5
years. Data concerning the fractional shortening (FS) value
were collected. Cardiac dysfunction was defined as a decrease
in FS <28% or a reduction of more than 10% [10]. Hearing
loss, a complication of cisplatin was defined according to
Brock Criteria [11] (grade 0: <40 dB at all frequencies;
grade1: ≥40 dB at 8000Hz; grade 2: ≥40 dB at 4000Hz;
grade3: ≥40 dB at 2000Hz; grade 4: ≥40 dB at 1000Hz). For
this analysis only survivors were included with a baseline
audiogram and an audiogram at the end of treatment.
3. Results and Discussion
3.1. Patients. The median age at diagnosis was 14.4 years
(range from 4.5 to 19.9 years). There were 72 male patients
(55.4%; median age: 14.8 years; range from 6.3 to 19.9 years)
and 58 female patients (44.6%; median age: 13.9 years; range
from 4.5 to 19.1 years). At diagnosis, 29 patients (22.3%) had
metastases and in 9 patients (6.6%) the tumor was located in
the axial skeleton.
3.2. Survival
3.2.1. Overall Survival. At a followup ranging between 4
and 33 years (median 8.9 years), 51 patients (39%) died.
Of all deaths, 45 were directly related to osteosarcoma
with 16 deaths due to progressive disease, eight due to
local recurrence, and 21 after the development of distant
metastases. The development of recurrent disease was pre-
dictive of death. Incidence of recurrences was relatively
stable after 5 years with only three patients developing
disease recurrence more than 5 years after diagnosis. Of the
remaining six patients that died, four patients developed a
second malignancy which was fatal, and two patients passed
away due to anthracycline-induced cardiomyopathy. The 5-
year OS of the whole population was 66.9% ± 0.15 the 10-
year OS was 64.6%± 0.23; the 20-year OS was 62.3%± 0.82.
These findings are in concordance with earlier reports in the
literature [12, 13]. In total, 60 patients had a followup longer
than 5 years, 38 patients were followed for more than 10
years, and a group of 20 patients was followed beyond 20
years. Comparison of the diﬀerent time periods of treatment
showed that the 5-year OS improved from 58.6% for children
diagnosed during 1979–1983 to 78.6% for those diagnosed
during 2003–2008 (P = 0.13; Figure 1). The distribution
of known prognostic factors, such as metastatic disease at
diagnosis, tumor location and good histologic response to
neoadjuvant chemotherapy, was comparable regarding the
diﬀerent time periods (Table 1).
3.2.2. Disease-Free Survival. The 5-year DFS of the whole
group was 59.2% ± 0.18. Patients with nonmetastatic osteo-
sarcoma disease showed a DFS of 65.3% versus 37.9% in
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Table 1: Distribution of prognostic factors over three decades.
Prognostic factor (N)
1979–1983 1984–2002 2003–2008
P
N = 29 N = 59 N = 42
Metastases at diagnosis 24.1% (7) 25.4% (15) 16.7% (7) 0.58
Tumor in axial skeleton 6.9% (2) 8.5% (5) 4.8% (2) 0.51
Good histologic response 24.1% (7) 23.7% (14) 35.7% (15) 0.55
>15% reduction due to toxicity 24.1% (7) 20.3% (12) 7.1% (3) 0.04
patients with metastases at diagnosis. During the past 3
decades the DFS of patients with metastases increased from
28.6% in 1979–1983, 40.0% in 1984–2002 to 42.9% in
2003–2008. The same trend is seen in patients with bad
histologic response to neoadjuvant chemotherapy: 5-year
DFS increased from 30.0% in 1979–1983, 57.6% in 1984–
2002 to 65.4% in 2003–2008. Comparison of DFS in patients
with axial involvement was not possible due to a small group.
3.3. Treatment
3.3.1. Chemotherapeutic Treatment. In the first era, surgical
resection was performed after 4 weeks of neoadjuvant
chemotherapy, after 1984 resection was performed in the
10th week of induction therapy. Good histologic response
to neoadjuvant chemotherapy was observed in 13.3% of
patients treated with cisplatin and doxorubicin and in
29.4% of patients additionally treated with methotrexate
(P = 0.083). Although an increased rate of good histologic
responders was seen in the group additionally treated
with methotrexate, comparing the regimen arms with and
without methotrexate, no evident diﬀerence was seen in 5-
year OS (HR = 0.75; 95% CI = 0.39–1.27; P = 0.24) or 5-year
DFS (HR = 0.75; 95%CI = 0.43–1.29; P = 0.29). The eﬀect of
high-dose methotrexate in the treatment of osteosarcoma is
not unambiguously proven in the literature. Several studies
have shown a relationship between peak serum concen-
trations of methotrexate and improved histologic response
[14–16]. However, a Cochrane systematic review comparing
the eﬀectiveness of methotrexate was unable to make clear
conclusions due to the lack of randomized controlled trials
using high-dose methotrexate as the only diﬀerence between
the intervention and control group [17].
3.3.2. Toxicity-Related Treatment Reduction. Chemotherapy
was reduced due to severe bone marrow depression (N = 6),
renal toxicity (N = 3), ototoxicity (N = 3), cardiotox-
icity (N = 3), and adverse eﬀects to methotrexate, like
methotrexate encephalopathy (N = 1) or allergic reactions
to methotrexate (N = 3). Interestingly, treatment reduction
due to acute toxicity is less frequent in patients treated
between 2003 and 2008 than in patients treated between 1984
and 1998 and in patients treated between 1979 and 1983
(P = 0.04, Table 1).
3.3.3. Surgical Treatment. Analysis of surgical treatment
method showed a rise from 26.9% of patients with limb
salvage treatment in 1979–1983 to 69% in 2003–2008.
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Figure 1: 5-year overall survival in pediatric patients with osteosar-
coma over three decades.
The 5-year DFS rates were 57.8% for limb salvage treatment
and 66.1% for amputation (HR = 1.35; 95% CI = 0.76–2.39;
P = 0.30). The advancement of patients with limb salvage
treatment could be expected considering that amputation
patients might have had more advanced disease. A slightly
but not significant improvement of DFS was seen in both
surgical methods over the past three decades (data not
shown).
3.4. Long-Term Toxicity
3.4.1. Secondary Malignancy Neoplasm. In total, seven
patients (5.3%) developed a second malignancy, with a
median latency from original diagnosis to second malig-
nancy of 12 years (range 2.4–23 years). Second malignancies
were two patients with acute lymphatic leukemia, four
patients with breast cancer, and one patient with gastric
adenocarcinoma. Of the seven patients who developed
secondary malignancy neoplasm (SMN), two patients had a
history of Li-Fraumeni syndrome. Both patients developed
SMN within 5 years after treatment of osteosarcoma. The 5-
and 10-year estimated cumulative SMN incidence rates were
1.5% ± 1.1% and 3.1% ± 1.3%, respectively, which is similar
to earlier studies in survivors of osteosarcoma [18, 19].
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Overall, the incidence ratio of secondary malignancies in
long-term survivors of osteosarcoma is much less compared
to other malignancies, for example, Hodgkin disease [20].
However, the cohort has been followed for a median of 8.9
years, and it is likely that with increasing followup, second
malignancies will emerge, due to a latency of 10 to 15 years.
3.4.2. Cardiotoxicity. In 46 patients suﬃcient data concern-
ing baseline and followup echocardiogram was available.
No patient had clinically evident cardiac disease before
chemotherapy. Before starting therapy with doxorubicin the
median FS value was 36%. In 8 patients the FS decreased
<28% during therapy, with a median change in the percent
FS value of 4% which is in concordance with earlier
studies on this subject [21]. The long-term implications of
doxorubicin-associated echocardiographic abnormalities are
not fully understood, but at least one study suggests that
echocardiographic abnormalities are progressive over time
[22]. In our cohort, three patients with decreased FS during
therapy remained to have cardiac dysfunction after finishing
primary treatment. In total, 11 out of 46 patients developed
cardiac dysfunction in the followup period. The median
frequency of cardiac evaluation in the first five years was
three (range: 1–5). The median latency of cardiac eﬀects
after finishing primary therapy was 219 days (range: from
30 days to 28.2 years). Six out of 11 patients with cardiac
dysfunction experienced symptomatic heart failures, four of
them more than 5 years after primary treatment and regular
controls. Two patients died of cardiomyopathy and three
of metastatic disease, which occurred after the diagnosis
of cardiomyopathy. Aﬀected patients were predominantly
treated in the first two decades of our study realizing that
the last cohort treated might not had enough followup to
adequately evaluate this late sequelae. All patients received
a mean cumulative doxorubicin dose of 450mg/m2.
3.4.3. Ototoxicity. Cisplatin-associated hearing loss develops
in the period when cisplatin is administered, and it has
already been observed in patients treated with a single dose
of 50mg/m2 [23]. However, it is unlikely to improve over
time, and as even mild hearing loss can have considerable
impact on the social-emotional development of a child
[24], it is considered to be one of the late eﬀects in the
treatment of osteosarcoma patients. Of the 79 survivors in
our study, 62 (78.5%) had an audiogram at the end of
treatment. Preexisting hearing loss was not reported in one
of these patients. Of the 62 survivors with an audiogram,
31 patients (50%) had no hearing loss, 23 patients (37.1%)
were Brock grade I, and 7 patients (11.1%) developed severe
hearing loss (Brock grades 3 and 4). All patients with
severe hearing loss required hearing aids. No diﬀerence was
seen in cumulative dosage of cisplatin comparing patients
with severe hearing loss (cumulative dosage: 407mg/m2)
versus patients with grade 0,1 or 2 hearing loss (cumulative
dosage: 442mg/m2, P = 0.55). Furthermore, no diﬀerence
in prevalence of severe ototoxicity was seen between the drug
regimens using either 600mg/m2 or 480mg/m2 cisplatin
(P = 0.25) or continuous infusion versus repeated 6-hour
infusions (P = 0.76).
Like other studies in childhood cancer [25] we showed
an improved survival of patients with osteosarcoma over
the past decades. This improvement is seen in all subgroups
irrespective of known prognostic factors like metastases at
diagnosis or histological response to neoadjuvant therapy.
This increase in childhood cancer survival is often attributed
to more eﬀective treatment strategies. However, in our study
the treatment agents and dosage basically remained the same
over the past 30 years with cumulative doses of doxorubicin
450mg/m2, cisplatin 480 or 600mg/m2, and high-dose
methotrexate 96–144 g/m2 appropriate to age. Furthermore,
there was no diﬀerence in method of administration regard-
ing doxorubicin and high-dose methotrexate. Cisplatin was
administered as a 6-hour infusion during 1979–1983 in our
study and then as continuous infusion. While continuous
cisplatin infusions are observed to be considerably ototoxic
(Lanvers-Kaminsky PBC 2006 [26]), we found no diﬀerence
in our study. Therefore, other factors like empiric use of
broad spectrum antibiotics in case of neutropenic fever, pain
management, antiemetics, nutrition, blood banking, and
improved pediatric intensive care might have improved the
acceptability of the current treatment. On the other hand,
with an increasing number of cancer survivors detection
of late eﬀects of osteosarcoma therapy is required. In this
study, we show that late cardiac eﬀects and SMN can become
evident many years after treatment and can have profound
impact on cancer survivors.
In conclusion, these data elucidate the prevalence of tox-
icity to therapy in children with osteosarcoma. Further stud-
ies concerning the management of long-term toxicities are
needed to finally improve survival rates in patients with
osteosarcoma.
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